Frontiers in Immunology (Dec 2021)

HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation

  • Chrysanthi Tsamadou,
  • Chrysanthi Tsamadou,
  • Daphne Engelhardt,
  • Daphne Engelhardt,
  • Uwe Platzbecker,
  • Elisa Sala,
  • Thomas Valerius,
  • Eva Wagner-Drouet,
  • Gerald Wulf,
  • Nicolaus Kröger,
  • Niels Murawski,
  • Hermann Einsele,
  • Kerstin Schaefer-Eckart,
  • Sebastian Freitag,
  • Jochen Casper,
  • Martin Kaufmann,
  • Mareike Dürholt,
  • Bernd Hertenstein,
  • Stefan Klein,
  • Mark Ringhoffer,
  • Sandra Frank,
  • Christine Neuchel,
  • Christine Neuchel,
  • Hubert Schrezenmeier,
  • Hubert Schrezenmeier,
  • Joannis Mytilineos,
  • Joannis Mytilineos,
  • Daniel Fuerst,
  • Daniel Fuerst

DOI
https://doi.org/10.3389/fimmu.2021.771449
Journal volume & issue
Vol. 12

Abstract

Read online

The HLA-DRB3/4/5 loci are closely linked to the HLA-DRB1 gene. Mismatches in these loci occur with a frequency of about 8%–12% in otherwise 10/10 HLA-matched transplant pairs. There is preliminary evidence that these disparities may associate with increased acute graft-versus-host disease (GvHD) rates. The aim of this study was to analyze a large cohort of German patients and their donors for HLA-DRB3/4/5 compatibility and to correlate the HLA-DRB3/4/5 matching status with the outcome of unrelated hematopoietic stem cell transplantation (uHSCT). To this end, 3,410 patients and their respective donors were HLA-DRB3/4/5 and HLA-DPB1 typed by amplicon-based next-generation sequencing (NGS). All patients included received their first allogeneic transplant for malignant hematologic diseases between 2000 and 2014. Mismatches in the antigen recognition domain (ARD) of HLA-DRB3/4/5 genes were correlated with clinical outcome. HLA-DRB3/4/5 incompatibility was seen in 12.5% (n = 296) and 17.8% (n = 185) of the 10/10 and 9/10 HLA-matched cases, respectively. HLA-DRB3/4/5 mismatches in the ARD associated with a worse overall survival (OS), as shown in univariate (5-year OS: 46.1% vs. 39.8%, log-rank p = 0.038) and multivariate analyses [hazard ratio (HR) 1.25, 95% CI 1.02–1.54, p = 0.034] in the otherwise 10/10 HLA-matched subgroup. The worse outcome was mainly driven by a significantly higher non-relapse mortality (HR 1.35, 95% CI 1.05–1.73, p = 0.017). In the 9/10 HLA-matched cases, the effect was not statistically significant. Our study results suggest that mismatches within the ARD of HLA-DRB3/4/5 genes significantly impact the outcome of otherwise fully matched uHSCT and support their consideration upon donor selection in the future.

Keywords